HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on ASLAN Pharma (NASDAQ:ASLN) and maintained a price target of $17.
November 06, 2023 | 11:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ASLAN Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $17.
The reiteration of a 'Buy' rating and maintenance of a $17 price target by HC Wainwright & Co. indicates a positive outlook for ASLAN Pharma. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100